Trial Profile
A post-marketing clinical study to evaluate the efficacy and safety of pertuzumab combined with trastuzumab and docetaxel as first line treatment in HER2- positive inoperable or recurrent breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms COMACHI
- Sponsors Chugai Pharmaceutical
- 17 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Mar 2019.
- 10 Jun 2016 New trial record